New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 24, 2014
07:07 EDTRPTPRaptor Pharmaceuticals announces publication of PROCYSBI data
Raptor Pharmaceutical announced that data from its open label extension study of delayed-release cysteamine bitartrate, or PROCYSBI, has been published in the Journal of Pediatrics. The study demonstrated that patients with nephropathic cystinosis who took PROCYSBI for two years were able to sustain optimal cystine control in their white blood cells and preserve kidney function over the long term, and had significant improvements in social, school and total functioning based on validated quality of life measurement scales. There were no unexpected or serious safety concerns attributable to PROCYSBI. All 40 patients experienced one or more treatment-emergent adverse events.
News For RPTP From The Last 14 Days
Check below for free stories on RPTP the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
September 15, 2014
08:58 EDTRPTPRaptor Pharma should be owned ahead of potential catalysts, says JMP Securities
JMP Securities believes that Raptor has a number of potentially transformative upcoming catalysts. The firm thinks that adoption of the company's Proscybi drug could be a number of times higher than current levels, and it thinks that data due to be released over the next several months could be transformative for the company. The firm reiterates a $33 price target and Outperform rating.
September 11, 2014
09:38 EDTRPTPRaptor Pharmaceuticals management to meet with JMP Securities
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use